Cerebras, Cisco shares sink despite strong AI demand data
Shares of Cerebras Systems and Cisco Systems fell on Thursday despite reporting strong demand for AI infrastructure. Cerebras saw core revenue rise 103% year over year, while Cisco booked $4 billion in Q4 hyperscaler AI orders. However, investors reacted negatively to Cerebras' slowed sequential growth guidance and Cisco's already priced-in optimism.

*this image is generated using AI for illustrative purposes only.
Cerebras Systems Inc. (NASDAQ: CBRS) and Cisco Systems Inc. (NASDAQ: CSCO) shares declined significantly on Thursday, despite both companies presenting fresh evidence of sustained demand in the AI infrastructure sector. Cerebras fell 13% and Cisco dropped approximately 8% at the time of writing, signaling a shift in investor priorities from raw demand metrics to growth acceleration and margin sustainability.
Strong Demand Metrics
Cerebras reported record core revenue of $209.9 million, representing a 103% increase year over year. Core cloud and services revenue surged 287%. The company’s remaining performance obligations reached $25.4 billion, prompting an upgrade to its full-year guidance.
Cisco also demonstrated robust order inflow, booking $4 billion in hyperscaler AI infrastructure orders during the fourth quarter. This brought fiscal 2026 total orders to $9.3 billion. Cisco expects $7.5 billion in hyperscaler AI revenue for fiscal 2027. Total revenue rose 18% to $17.25 billion, beating analyst estimates.
| Company | Key Metric | Value | Change |
|---|---|---|---|
| Cerebras | Core Revenue | $209.9 million | +103% YoY |
| Cerebras | Remaining Performance Obligations | $25.4 billion | N/A |
| Cisco | Hyperscaler AI Orders (Q4) | $4 billion | N/A |
| Cisco | Fiscal 2026 Total Orders | $9.3 billion | N/A |
| Cisco | Revenue | $17.25 billion | +18% YoY |
Growth Deceleration Concerns
The market reaction suggests investors are increasingly focused on the rate of acceleration rather than absolute growth figures. Jake Behan, Direxion’s head of capital markets, noted that Cisco entered earnings with considerable optimism already priced in, meaning strong results were viewed as confirmation rather than a new catalyst.
Cerebras guided third-quarter core revenue to between $214 million and $216 million. This implies just 2.4% sequential growth at the midpoint, a sharp deceleration from the triple-digit annual growth seen previously. Additionally, Cerebras expects core gross margin to contract to 38%-40% before recovering in the fourth quarter.
What the Numbers Show
The divergence between Cerebras’ annual performance and its forward guidance highlights a critical tension in the current AI trade. While the company achieved a 103% year-over-year revenue increase, the implied sequential growth of only 2.4% for the next quarter suggests that the base effect is fading faster than anticipated. This slowdown, combined with expected margin compression, indicates that execution risks are rising as the company scales capacity to meet its $25.4 billion backlog.
Market Sentiment and Outlook
Prediction-market data indicates skepticism about an imminent breakdown in the broader AI boom. Polymarket odds of a severe AI-industry downturn by year-end stood at 14%, down from 27% in late July, based on roughly $2.9 million in trading volume.
Morgan Stanley analysts stated that "execution remains the key debate" for Cerebras given the scale and speed of the capacity build required. Investor Dan Ives described Cisco and CoreWeave as "pieces of the puzzle" for the AI trade, arguing the narrative is shifting beyond capital expenditure toward monetization. The reactions to both companies underscore that investors now require evidence that strong demand translates into accelerating revenue growth and expanding margins.
How will Cerebras' projected margin compression in Q3 impact its ability to maintain profitability while scaling capacity for its $25.4 billion backlog?
Could Cisco's shift from order volume to revenue recognition signal a broader market pivot where investors prioritize monetization efficiency over capital expenditure growth?
What specific operational hurdles must Cerebras overcome to ensure its Q4 margin recovery materializes as guided, given the execution risks highlighted by Morgan Stanley?

































